Italiano Antoine, Professor of Medicine, Head of Early Phase Trials Unit at Institut Bergonié and Head of Precision Medicine at Gustave Roussy, shared a post on LinkedIn:
”Radionuclide therapies are poised to spark a new revolution in the management of cancer patients — bringing true precision to systemic treatments.
I had the pleasure of chairing the symposium at EANM 2025 in Barcelona, titled ‘From Pan-Tumor Innovation to Theranostic Precision – FAP and CAIX Case Studies.’
My sincere thanks to our outstanding speakers — Dr. Yuriko Mori, Prof. Richard P. Baum, Prof. Daniela Oprea-Lager, and Dr. Cristina Suárez — for their brilliant presentations and thought-provoking discussions.
Together, we explored how FAP- and CAIX-targeted approaches are redefining the theranostic landscape, with advances in radioligand therapy, quantitative imaging, AI-guided dosimetry, and pan-tumor applications that are accelerating the translation of molecular innovation into clinical benefit.
A big thank-you as well to the Telix team and to all colleagues who joined the discussion — your energy and vision continue to drive our field forward.”
More from Italiano Antoine on OncoDaily.